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LETTERS
Injectional Anthrax 
in Heroin Users,  
Europe, 2000–2012
To the Editor: Anthrax is a glob-
al zoonotic disease, but human infec-
tions are rare in countries of Western 
Europe. During 2009–2010, a total of 
119 (47 laboratory-confirmed) drug-
abuse–related cases of anthrax were 
reported in the United Kingdom and 
Germany (1). In these patients, the 
disease had an unusual manifestation. 
In contrast to acquiring the disease 
through typical routes of infection, 
leading to cutaneous, inhalation, or 
gastrointestinal anthrax, these patients 
became infected by injecting heroin 
(1–3). The term injectional anthrax 
was then coined to describe this new 
mode of infection. Patients with injec-
tional anthrax show severe symptoms, 
and death rates are high. Of the 47 
patients with confirmed cases of in-
jectional anthrax acquired during the 
2009–2010 outbreak, 19 died from the 
disease (1). However, this outbreak 
was not the first report of death caused 
by B. anthracis in an injectional drug 
(heroin) user; the disease was de-
scribed in 1 person who died in Nor-
way in 2000 (3).
Attempts to directly connect the 
United Kingdom cases to batches of 
anthrax-contaminated heroin were un-
successful. No viable B. anthracis or 
DNA could be retrieved from the in-
vestigation’s drug samples. However, 
PCR- or culture-positive samples 
were obtained from some patients 
and used for genotyping (2). Later, re-
searchers from Arizona and the United 
Kingdom worked together to use a 
high-resolution molecular approach 
to genotype the 2009–2010 outbreak 
strains. This information was used to 
obtain insight into the epidemiology 
and likely geographic origin of the 
European outbreak strains. 
All patients were infected by 
a single B. anthracis strain type 
(2,4) that belonged to the large 
Trans-Eurasian clade of B. anthracis. 
The whole genome of a representative 
strain of this type, Ba4599, had previ-
ously been sequenced (2). Strains re-
lated to strains associated with those 
isolated from European drug users, 
which belong to the A.Br. 008/011 
canSNP cluster but are still geneti-
cally distinct, have so far only been 
identified from Turkey (2). However, 
more isolates from other relevant re-
gions need to be investigated to con-
firm the likely geographic source.
In June 2012, after a 20-month 
gap, 2 new cases of injectional anthrax 
in heroin consumers were reported in 
Bavaria (5,6). Additional cases have 
been reported since then from Ger-
many, Denmark, the United Kingdom, 
and France, leading to 26 deaths as of 
August 2013 (7). 
Molecular phylogenetic methods 
were used to determine the genetic re-
latedness of these strains with Ba4599 
(8,9). Genotyping results using canon-
ical single nucleotide polymorphisms 
(SNPs) (Figure) (2,4) placed all of 
these strains along branch A.Br.008 
within the Trans-Eurasian group of 
B. anthracis (10). Further hierarchi-
cal fine-scale typing of the isolates by 
interrogating SNPs that were discov-
ered from the heroin-associated strain 
Ba4599 (2) indicated that all isolates 
are identical at these SNPs (Figure) 
(7). The initial  strain isolated in Nor-
way in 2000 also falls into this group 
(7). In addition, analysis by multiple 
locus variable number tandem repeats 
suggested that all investigated strains 
are closely related, differing at just 2 
markers (7). Thus, we conclude that 
all injectional anthrax isolates likely 
came from the same source.
This reemergence of drug-relat-
ed anthrax in Europe strengthens the 
view that heroin may provide a con-
tinuing route of entry for B. anthracis 
into Western Europe (2). Ideally, this 
unfortunate deadly incident could of-
fer an opportunity to sensitize heroin 
users to the risks for severe infection 
and to educate public health officials 
to be vigilant for this rare disease. 
This study also shows the power of 
molecular genotyping approaches for 
trace-back analysis of infectious dis-
ease agents.
322	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	20,	No.	2,	February	2014
Figure.	 Diagram	 of	 single	
nucleotide	 polymorphism	 (SNP)	
assays	 used	 for	 bioforensic	
genotyping	 of	 heroin-associated	
Bacillus anthracis	 strains.	 Shown	
are	the	results	of	PCR-based	SNP	
assays	 performed	 to	 elucidate	 the	




black	 line	 indicates	 the	 assays	 in	
a	 direction	 of	 revealing	 increasing	
proximity	 to	 the	 heroin-associated	
strains.	 SNPs	 common	 to	 those	
of	 some	 strains	 from	 Turkey	 (2)	
are	shown	 in	 light	gray,	and	SNPs	
unique	 for	 the	 heroin-associated	
strains	 (2),	 including	 the	 isolate	 of	
2000	from	Norway,	are	depicted	in	





We thank Daniela Horenkamp and 
Claudia Kahlhofer for skillful technical 
assistance and Holger C. Scholz, Roland 
Grunow, and Dawn Birdsell for helpful 
discussions.
Collaboration between the Bunde-
swehr Institute of Microbiology and 
Northern Arizona University is part of a 
project funded by the US Department of 
Homeland Security Science and Technol-
ogy Directorate through award 2010-ST-
108-000015. This work was also supported 
in part by the US Department of Homeland 
Security Science and Technology Direc-
torate award HSHQDC-10-C-00139. 
Matthias Hanczaruk,  
Udo Reischl,  
Thomas Holzmann,  
Dimitrios Frangoulidis,  
David M. Wagner, Paul S. Keim, 
Markus H. Antwerpen,  




zaruk,	 D.	 Frangoulidis,	 M.H.	 Antwerpen,	
H.	 Meyer,	 G.	 Grass);	 University	 Hospi-
tal	 Regensburg,	 Regensburg,	 Germany	 





  1. Health Protection Scotland. An outbreak 
of anthrax among drug users in Scot-
land, December 2009 to December 2010. 
A report on behalf of the national Anthrax 
Outbreak Control Team. 2011 [cited 2013 
Aug 20].  http://www.documents.hps.
scot.nhs.uk/giz/anthrax-outbreak/anthrax- 
outbreak-report-2011-12.pdf 
  2. Price EP, Seymour ML, Sarovich DS, 
Latham J, Wolken SR, Mason J, et al. 
The molecular epidemiologic inves-
tigation of an anthrax outbreak in 
European heroin users. Emerg Infect 
Dis. 2012;18:1307–13. http://dx.doi.
org/10.3201/eid1808.111343
  3. Ringertz SH, Hoiby EA, Jensenius M, 
Maehlen J, Caugant DA, Myklebust 
A, et al. Injectional anthrax in a heroin 
skin-popper. Lancet. 2000;356:1574–5. 
http://dx.doi.org/10.1016/S0140-6736(00) 
03133-0
  4. Van Ert MN, Easterday WR, Huynh LY, 
Okinaka RT, Hugh-Jones ME, Ravel J, 
et al. Global genetic population struc-
ture of Bacillus anthracis. PLoS One. 
2007;2:e461. http://dx.doi.org/10.1371/
journal.pone.0000461
  5. Holzmann T, Frangoulidis D, Simon M, 
Noll P, Schmoldt S, Hanczaruk M, et al. 
Fatal anthrax infection in a heroin user 
from southern Germany, June 2012. Euro 
Surveill. 2012;17:pii=20204. 
  6. Rückert C, Licht K, Kalinowski J, Espirito 
Santo C, Antwerpen M, Hanczaruk M, et 
al. Draft genome sequence of Bacillus 
anthracis UR-1, isolated from a German 
heroin user. J Bacteriol. 2012;194:5997–8. 
http://dx.doi.org/10.1128/JB.01410-12
  7. Grunow R, Klee SR, Beyer W, George 
M, Grunow D, Barduhn A, et al. Anthrax 
among heroin users in Europe possibly 
caused by same Bacillus anthracis 
strain since 2000. Euro Surveill. 
2013;18:pii=20204.
  8. Antwerpen MH, Zimmermann P, Bewley 
K, Frangoulidis D, Meyer H. Real-time 
PCR system targeting a chromosomal 
marker specific for Bacillus anthracis. 
Mol Cell Probes. 2008;22:313–5. http://
dx.doi.org/10.1016/j.mcp.2008.06.001
  9. Ellerbrok H, Nattermann H, Ozel M, 
Beutin L, Appel B, Pauli G. Rapid 
and sensitive identification of patho-
genic and apathogenic Bacillus anthra-
cis by real-time PCR. FEMS Micro-
biol Lett. 2002;214:51–9. http://dx.doi.
org/10.1111/j.1574-6968.2002.tb11324.x
10. Price EP, Seymour ML, Sarovich DS, 
Latham J, Wolken SR, Mason J, et al. 
Molecular epidemiologic investigation of an 
anthrax outbreak among heroin users, 
Europe. Emerg Infect Dis. 2012;18:1307–13. 
http://dx.doi.org/10.3201/eid1808.111343
Address for correspondence: Gregor Grass, 
Bundeswehr Institute of Microbiology, 






To the Editor: Xu and colleagues 
(1) examined the nasopharyngeal 
bacterial colonization rates in chil-
dren with acute otitis media (AOM) 
and in healthy children. They found 
that Haemophilus influenzae coloni-
zation was competitively associated 
with Streptococcus pneumoniae and 
Morexella catarrhalis colonization in 
children with AOM but was not as-
sociated with S. pneumoniae and M. 
catarrhalis colonization in healthy 
children. We have a serious concern 
regarding their analysis.
The authors calculated odds ra-
tios (ORs) by considering a bacterial 
colonization as an outcome variable 
and another bacterial colonization as 
an exposure variable. They considered 
an OR >1 as the presence of syner-
gistic associations between bacteria 
(i.e., co-colonization is more likely 
to occur than it would by chance) and 
OR <1 as the presence of competi-
tive associations (i.e., co-colonization 
is less likely to occur than it would 
by chance). This inference may be 
justified in a population-based cross-
sectional study. If 2 bacterial coloni-
zations occur independently in a sta-
tionary population, the prevalence of 
co-colonization will be the product 
(multiplication) of each prevalence, 
and the OR between 2 bacterial colo-
nizations in the population (ORpop) 
will be 1 (online Technical Appendix, 
wwwnc.cdc.gov/EID/article/20/2/12-
1724-Techapp1.pdf).
However, the authors enrolled 
their case-patients according to clini-
cal signs (i.e., AOM or healthy). Let us 
assume that case-patients are enrolled 
from a population of children during 
a time period of t. Let rc be the risk 
for enrollment (that is, of developing 
the disease) among colonized chil-
dren and rn be the risk for enrollment 
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